IL118778A - Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor - Google Patents

Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor

Info

Publication number
IL118778A
IL118778A IL11877896A IL11877896A IL118778A IL 118778 A IL118778 A IL 118778A IL 11877896 A IL11877896 A IL 11877896A IL 11877896 A IL11877896 A IL 11877896A IL 118778 A IL118778 A IL 118778A
Authority
IL
Israel
Prior art keywords
dione
xanthoma
hmg
coa reductase
arteriosclerosis
Prior art date
Application number
IL11877896A
Other languages
English (en)
Other versions
IL118778A0 (en
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15847039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL118778(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of IL118778A0 publication Critical patent/IL118778A0/xx
Publication of IL118778A publication Critical patent/IL118778A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Glass Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL11877896A 1995-07-03 1996-07-02 Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor IL118778A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16729195 1995-07-03

Publications (2)

Publication Number Publication Date
IL118778A0 IL118778A0 (en) 1996-10-31
IL118778A true IL118778A (en) 1999-07-14

Family

ID=15847039

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11877896A IL118778A (en) 1995-07-03 1996-07-02 Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor

Country Status (20)

Country Link
US (2) US5798375A (no)
EP (1) EP0753298B2 (no)
KR (1) KR100424124B1 (no)
CN (1) CN1089584C (no)
AT (1) ATE209046T1 (no)
AU (1) AU706628B2 (no)
CA (1) CA2180296C (no)
CZ (1) CZ286832B6 (no)
DE (1) DE69617116T3 (no)
DK (1) DK0753298T3 (no)
ES (1) ES2165474T5 (no)
HK (1) HK1011928A1 (no)
HU (1) HUP9601808A3 (no)
IL (1) IL118778A (no)
NO (1) NO318765B1 (no)
NZ (1) NZ286920A (no)
PT (1) PT753298E (no)
RU (1) RU2158607C2 (no)
TW (1) TW474809B (no)
ZA (1) ZA965650B (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DE69739828D1 (de) * 1996-12-11 2010-05-12 Dana Farber Cancer Inst Inc Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
SI1009400T1 (en) * 1997-08-29 2005-04-30 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
ES2221203T3 (es) * 1997-10-08 2004-12-16 Sankyo Company Limited Compuesto heterociclico fusionado sustituido.
EP1047423B1 (en) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Novel apoptosis inhibitors
US20030105154A1 (en) 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6489344B1 (en) 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7141602B2 (en) * 1998-09-18 2006-11-28 Lek Pharmaceuticals D.D. Process for obtaining HMG-CoA reductase inhibitors of high purity
US6326396B1 (en) 1998-11-20 2001-12-04 Alteon, Inc. Glucose and lipid lowering compounds
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
TWI284533B (en) 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
CN1378547A (zh) 1999-10-11 2002-11-06 辉瑞大药厂 用作磷酸二酯酶抑制剂的5－(2－取代的－5－杂环基磺酰基吡啶－3－基)－二氢吡唑并[4,3－d]嘧啶－7－酮类化合物
US20030060488A1 (en) * 2000-02-10 2003-03-27 Yasuo Sugiyama Drug comprising combination
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
ES2401598T3 (es) * 2000-04-10 2013-04-22 Teva Pharmaceutical Industries, Ltd. Composiciones farmacéuticas estables que contienen ácidos 7-sustituido-3,5-dihidroxiheptanoicos o ácidos 7-sustituido-3,5-dihidroxiheptenoicos
FR2807944B1 (fr) * 2000-04-25 2003-06-13 Solvay Pharma Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament
SI1292293T1 (en) 2000-06-09 2004-06-30 LEK farmacevtska dru�ba d.d. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
TWI284529B (en) * 2000-12-18 2007-08-01 Sankyo Co A composition for lowering triglyceride
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
WO2002051396A1 (fr) * 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions pharmaceutiques contenant des derives de cyclobutene
EP1372616A4 (en) * 2001-03-27 2004-06-23 Ranbaxy Lab Ltd STABLE PHARMACEUTICAL COMPOSITION BASED ON PRAVASTATIN
WO2002087580A1 (fr) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Promoteurs d'expression d'abc
US6486127B1 (en) 2001-05-23 2002-11-26 Insmed, Incorporated Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
MXPA04002573A (es) * 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US9345671B2 (en) * 2003-04-28 2016-05-24 Daiichi Sankyo Company, Limited Adiponectin production enhancer
AU2004233691B2 (en) * 2003-04-28 2007-09-20 Sankyo Company, Limited Sugar intake-ability enhancer
CA2526730A1 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
BRPI0412009A (pt) * 2003-06-27 2006-08-15 Reddy Research Foundation composições compreendendo balaglitazona e outros compostos antidiabéticos
US6978908B2 (en) * 2003-09-15 2005-12-27 Gerber Products Company Drinking vessel with adjustable handles
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) * 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) * 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
SG166829A1 (en) 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
EP1984026B1 (en) * 2006-01-30 2013-05-01 Ben David Bryson Israel Compositions treating cardiovascular, cerebrovascular and other vascular disease patients
NZ571870A (en) * 2006-03-16 2011-07-29 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
RU2445957C2 (ru) 2006-03-16 2012-03-27 Метаболик Солюшнз Девелопмент Компани Аналоги тиазолидиндиона
US20080051417A1 (en) * 2006-07-18 2008-02-28 Yochai Birnbaum Uses of selective cyclooxygenase-1 inhibitors
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
PL2203433T3 (pl) 2007-09-14 2013-04-30 Metabolic Solutions Dev Co Llc 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy
EP2513070B1 (en) 2009-12-15 2017-11-08 Cirius Therapeutics, Inc. Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
MX2018005540A (es) 2015-11-06 2018-11-09 Gemphire Therapeutics Inc Tratamiento de dislipemia mixta.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
IL60219A (en) * 1979-06-15 1985-05-31 Merck & Co Inc Hypocholesteremic fermentation products of the hmg-coa reductase inhibitor type,their preparation and pharmaceutical compositions containing them
AU548996B2 (en) * 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469383A (ja) * 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
CA2118706A1 (en) * 1992-07-13 1994-01-20 Saizo Shibata Novel thiazolidinedione compounds and use thereof
JPH0741423A (ja) * 1993-02-24 1995-02-10 Sankyo Co Ltd 動脈硬化症治療剤
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
NO305987B1 (no) * 1994-04-11 1999-08-30 Sankyo Co Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
CZ261095A3 (en) * 1994-10-07 1996-04-17 Sankyo Co Oxime derivatives, process of their preparation, pharmaceutical composition containing thereof and their use
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR19990087076A (ko) * 1996-04-05 1999-12-15 다께다 구니오 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물
JP2002504137A (ja) * 1997-06-18 2002-02-05 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー チアゾリジンジオンおよびメトホルミンを用いる糖尿病の治療

Also Published As

Publication number Publication date
HUP9601808A3 (en) 2000-06-28
CN1148492A (zh) 1997-04-30
NO962784L (no) 1997-01-06
ES2165474T3 (es) 2002-03-16
CZ198296A3 (en) 1997-01-15
DE69617116T3 (de) 2011-10-06
ES2165474T5 (es) 2011-06-08
CZ286832B6 (en) 2000-07-12
DE69617116T2 (de) 2002-08-29
NO962784D0 (no) 1996-07-02
TW474809B (en) 2002-02-01
HUP9601808A2 (en) 1997-04-28
RU2158607C2 (ru) 2000-11-10
CA2180296C (en) 2007-01-09
NO318765B1 (no) 2005-05-02
DK0753298T3 (da) 2002-05-21
AU706628B2 (en) 1999-06-17
CA2180296A1 (en) 1997-01-04
ATE209046T1 (de) 2001-12-15
DE69617116D1 (de) 2002-01-03
US5798375A (en) 1998-08-25
KR100424124B1 (ko) 2004-06-26
IL118778A0 (en) 1996-10-31
CN1089584C (zh) 2002-08-28
ZA965650B (en) 1997-01-27
EP0753298B1 (en) 2001-11-21
AU5626196A (en) 1997-01-16
KR970005307A (ko) 1997-02-19
PT753298E (pt) 2002-03-28
US6159997A (en) 2000-12-12
EP0753298B2 (en) 2011-02-16
NZ286920A (en) 1997-06-24
EP0753298A1 (en) 1997-01-15
HK1011928A1 (en) 1999-07-23

Similar Documents

Publication Publication Date Title
IL118778A0 (en) Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an HMG-CoA reductase inhibitor
RU96112769A (ru) Лечение артериосклероза и ксантомы
IE970731A1 (en) Product and method for the treatment of hyperlipidemia
BG105559A (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
GB2262229B (en) Pharmaceutical compositions of pH at least 8 comprising an HMG-CoA reductase i nhibitor
HUT67023A (en) Monohydrate of 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-pierazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indole-5-one hydrochloride and pharmaceutical compositions containing that
AU6959898A (en) Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
DE69628874D1 (de) Verwendung eines HMG CoA-Reduktase Inhibitors zur Vorbeugung eines zweiten Herzanfalls
IL165816A0 (en) Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
WO1996009827A3 (en) Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
IL141785A0 (en) A pharmaceutical composition containing an ap2 inhibitor
WO2000048626A3 (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease
PL331339A1 (en) Antihrombotic and antiarteriosclerotic pharmaceutical composition containing derivative of thiene pyridine as well as an inhibitor of hmg-coa reductase
HK1003051A1 (en) Treatment and prophylaxis of pancreatitis
AU1680292A (en) Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen
ITRM920222A0 (it) Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
ZA9510970B (en) Synergistic combinations of 2-(thiocyanomethylthio) benzothiazole and thiophanate compounds useful as fungicides
TH27628B (th) การรักษาโรคผนังเส้นเลือกแดงหนาแข็งและแซนโธมา
BR9813539A (pt) Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas
CA2529367A1 (en) Preventing atrial fibrillation (af) with the use of statin drugs
CA2375378A1 (en) Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
JP2003524582A5 (no)
MX9602577A (es) Tratamiento de arterioesclerosis y xantoma.
CO5611117A2 (es) Combinacion de compuestos organicos
NO932874L (no) Anvendelse av lacidipin for behandling av arteriosklerose

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees